0001209191-20-039115.txt : 20200626
0001209191-20-039115.hdr.sgml : 20200626
20200626171050
ACCESSION NUMBER: 0001209191-20-039115
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20200618
FILED AS OF DATE: 20200626
DATE AS OF CHANGE: 20200626
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ciulla Thomas
CENTRAL INDEX KEY: 0001815426
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37783
FILM NUMBER: 20995022
MAIL ADDRESS:
STREET 1: C/O CLEARSIDE BIOMEDICAL, INC.
STREET 2: 900 NORTH POINT PARKWAY, SUITE 200
CITY: ALPHARETTA
STATE: GA
ZIP: 30005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clearside Biomedical, Inc.
CENTRAL INDEX KEY: 0001539029
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 452437375
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 900 NORTH POINT PARKWAY
STREET 2: SUITE 200
CITY: ALPHARETTA
STATE: 2Q
ZIP: 30005
BUSINESS PHONE: 678-270-3631
MAIL ADDRESS:
STREET 1: 900 NORTH POINT PARKWAY
STREET 2: SUITE 200
CITY: ALPHARETTA
STATE: 2Q
ZIP: 30005
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-06-18
0
0001539029
Clearside Biomedical, Inc.
CLSD
0001815426
Ciulla Thomas
C/O CLEARSIDE BIOMEDICAL, INC.
900 NORTH POINT PARKWAY, SUITE 200
ALPHARETTA
GA
30005
0
1
0
0
Chief Medical Officer
Common Stock
145000
D
Employee Stock Option (right to buy)
5.04
2028-10-24
Common Stock
80000
D
Employee Stock Option (right to buy)
1.24
2029-02-05
Common Stock
100000
D
Employee Stock Option (right to buy)
2.37
2030-01-08
Common Stock
75000
D
Includes 70,000 restricted stock units ("RSUs"). Fifty percent (50%) of the shares underlying these RSUs vest on September 18, 2020 and twenty-five percent (25%) of the remaining RSUs vest in four equal quarterly installments thereafter. Also includes an additional 50,000 RSUs. Twenty-five percent (25%) of the shares underlying these RSUs vest in four equal annual installments on January 8, 2021, January 8, 2022, January 8, 2023 and January 8, 2024. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Vesting is subject to the Reporting Person's continuous service as of each such vesting date, and subject to accelerated vesting in specified circumstances.
One-fourth of the shares underlying this option vested on October 24, 2019 and the balance of the shares vested or vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.
One-fourth of the shares underlying this option vested on February 5, 2020 and the balance of the shares vested or vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.
One-fourth of the shares underlying this option vest on January 8, 2021 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.
Exhibit List - Exhibit 24 - Power of Attorney
/s/ Mark Ballantyne, Attorney-in-Fact
2020-06-26
EX-24.3_924760
2
poa.txt
POA DOCUMENT
Exhibit 24
POWER OF ATTORNEY
(For Executing Form ID and Forms 3, 4 and 5)
Know all by these presents, that the undersigned hereby constitutes and
appoints each of Brent B. Siler, Brian F. Leaf, Mark Ballantyne, Asheley Walker
and Jason Minio of Cooley LLP, and George Lasezkay, Charles A. Deignan and
Leslie Zacks of Clearside Biomedical, Inc. (the "Company"), the undersigned's
true and lawful attorneys-in-fact and agents to:
(1) Prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the Securities and Exchange Commission (the "SEC") a Form ID,
Uniform Application for Access Codes to File on EDGAR, including amendments
thereto, and any other documents necessary or appropriate to obtain codes and
passwords enabling the undersigned to make electronic filings with the SEC of
reports required by Section 16(a) of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), or any rule or regulation thereunder;
(2) Prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the SEC Forms 3, 4 and 5 (including amendments thereto and joint
filing agreements in connection therewith) in accordance with Section 16(a) of
the Exchange Act and the rules thereunder in the undersigned's capacity as an
officer, director or beneficial owner of more than 10% of a registered class of
securities of the Company;
(3) Do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to prepare and execute any such Form 3, 4 or 5
(including amendments thereto and joint filing agreements in connection
therewith) and file such forms with the SEC and any stock exchange,
self-regulatory association or any similar authority; and
(4) Take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required of the undersigned, it being
understood that the documents executed by the attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as the attorney-in-fact may approve in the
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney in fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney in fact, or such attorney
in fact's substitute or substitutes, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers herein granted. The
undersigned acknowledges that the foregoing attorneys-in-fact, and their
substitutes, in serving in such capacity at the request of the undersigned, are
not assuming (nor is the Company assuming) any of the undersigned's
responsibilities to comply with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the Company and the foregoing attorneys-in fact or (c) as to any
attorney-in-fact individually, until such attorney-in-fact is no longer employed
by the Company or Cooley LLP, as applicable.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of the date written below.
Date: 16 - Jun - 2020
By: /s/ Thomas Ciulla
Thomas Ciulla